Erschienen in:
18.07.2020 | Hepatitis B (JK Lim, Section Editor)
Prevention and Management of HBV in Organ Transplantation
verfasst von:
Stela Celaj, Josh Levitsky
Erschienen in:
Current Hepatology Reports
|
Ausgabe 3/2020
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
Hepatitis B (HBV) infection and reactivation have a significant impact on solid organ transplantation. This review summarizes past significant studies and new findings in the field, and presents the latest recommendations for HBV management in solid organ transplant population.
Recent Findings
Significant advances in antiviral therapy have resulted in improved graft outcomes and have notably reduced the need for prophylaxis with hepatitis B immunoglobin. Emerging treatment avenues such as immunotherapies and small molecules inhibitors are being developed with the intent of eradicating HBV infection.
Summary
Substantial suppression of HBV is obtained with the current antiviral prophylaxis in transplant patients. This has allowed for safely expanding the donor pool to HBcAb-positive grafts with good outcomes. Novel therapies are showing a promising future for achieving functional cure for HBV.